BRPI0506909A - derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central - Google Patents

derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central

Info

Publication number
BRPI0506909A
BRPI0506909A BRPI0506909-2A BRPI0506909A BRPI0506909A BR PI0506909 A BRPI0506909 A BR PI0506909A BR PI0506909 A BRPI0506909 A BR PI0506909A BR PI0506909 A BRPI0506909 A BR PI0506909A
Authority
BR
Brazil
Prior art keywords
benzo
derivatives
dihydro
treatment
nervous system
Prior art date
Application number
BRPI0506909-2A
Other languages
English (en)
Inventor
Meng Sui
Shu-Hai Zhao
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0506909A publication Critical patent/BRPI0506909A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

DERIVADOS DE 1-BENZIL-5-PIPERAZIN-1-IL-3,4DIIDRO-1H-QUINAZOLIN-2-ONA E OS RESPECTIVOS DERIVADOS DE 1H-BENZO (1,2,6) TIADIAZINA-2,2-DIóXIDO E 1,4-DIIDRO-BENZO (D) (1,3)OXAZIN-2-ONA COMO MODULADORES DO RECEPTOR DE 5 HIDROXITRIPTAMINA (5-HT) PARA O TRATAMENTO DE DOENçAS DO SISTEMA NERVOSO CENTRAL. A presente invenção refere-se a compostos de quinazolina substituídos de fórmula (l) ou um sal farmaceuticamente aceitável desse, em que Y é C ou S; m é 1 quando Y é C e m é 2 quando Y é S; n é 1 ou 2; p é de 0 a 3; q é de 1 a 3; Z é -(CR~ a~ CR~ b~)r~- ou -SO~ 2~- em que r é de 0 a 2 e cada de R¬ a¬ e R¬ b¬ é independentemente hidrogênio ou alquila; X é CH ou N; R¬ 2¬ é arila opcionalmente substituída ou heteroarila opcionalmente substituída; preferivelmente R¬ 2¬ é arila, e mais preferivelmente fenila opcionalmente substituída por um ou mais trifluorometila, halo, ciano, C~ 1~-C~ 6~ alquila ou C~1-C~ 6~ alcóxi; A é -NR~ 3~- ou -O- em que R¬ 3¬ é: hidrogênio, alquila, acila, amidoalquila, hidroxialquila, ou alcoxialquila, os outros substituintes são definidos nas reivindicações. Os compostos são moduladores do receptor 5-hidroxitriptamina e são úteis para o tratamento de doencas do sistema nervoso central tais como psicose, esquizofrenia, depressões maníacas, distúrbios neurológicos, distúrbios de memória de distúrbio de déficit de atenção, doença de parkinson, esclerose lateral amiotrófica, doença de alzheimer, distúrbios de ingestãode alimentos, e doença de Huntington.
BRPI0506909-2A 2004-01-16 2005-01-07 derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central BRPI0506909A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53708004P 2004-01-16 2004-01-16
PCT/EP2005/000095 WO2005067933A1 (en) 2004-01-16 2005-01-07 1-benzyl-5-piperazin-1-yl-3,4 dihydro-1h-quinazolin-2-one derivatives and the respective 1h-benzo(1,2,6)thiadiazine-2,2-dioxide and 1,4-dihydro-benzo(d) (1,3)oxazin-2-one derivatives as modulators of the 5-hydroxytryptamine receptor (5-ht) for the treatment of diseases of the central nervous system

Publications (1)

Publication Number Publication Date
BRPI0506909A true BRPI0506909A (pt) 2007-05-29

Family

ID=34794441

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506909-2A BRPI0506909A (pt) 2004-01-16 2005-01-07 derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central

Country Status (19)

Country Link
US (2) US7196087B2 (pt)
EP (1) EP1708713B1 (pt)
JP (1) JP4533391B2 (pt)
KR (1) KR100843053B1 (pt)
CN (1) CN1909909B (pt)
AR (1) AR047958A1 (pt)
AT (1) ATE388712T1 (pt)
AU (1) AU2005205016B2 (pt)
BR (1) BRPI0506909A (pt)
CA (1) CA2552681A1 (pt)
CO (1) CO5700763A2 (pt)
DE (1) DE602005005298T2 (pt)
ES (1) ES2302174T3 (pt)
IL (1) IL176631A0 (pt)
NO (1) NO20062791L (pt)
RU (1) RU2006129464A (pt)
TW (1) TW200530222A (pt)
WO (1) WO2005067933A1 (pt)
ZA (1) ZA200605434B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2359725T3 (es) * 2004-09-30 2011-05-26 F. Hoffmann-La Roche Ag Composiciones y métodos para el tratamiento de trastornos cognitivos.
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1836183A2 (en) * 2004-12-13 2007-09-26 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
JP2009501184A (ja) * 2005-07-13 2009-01-15 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６、５−ｈｔ２４としてのベンゾイミダゾール誘導体
KR100817538B1 (ko) * 2006-07-05 2008-03-27 한국화학연구원 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물
JP5256202B2 (ja) * 2006-09-11 2013-08-07 エム・エス・ディー・オス・ベー・フェー キナゾリノンおよびイソキノリノンアセトアミド誘導体
US7718652B2 (en) 2006-12-12 2010-05-18 Wyeth Llc Substituted benzothiadiazinedioxide derivatives and methods of their use
JP2011524383A (ja) * 2008-06-20 2011-09-01 ロッタファルム・ソシエタ・ペル・アチオニ ６−１ｈ−イミダゾ−キナゾリンおよびキノリン誘導体、新規ｍａｏ阻害剤およびイミダゾリンレセプターリガンド
US8044047B2 (en) 2008-09-08 2011-10-25 Hoffman-La Roche Inc. 5-substituted benzoxazines
JP2013526590A (ja) 2010-05-21 2013-06-24 シェンヅェン サルブリス ファーマシューティカルズ カンパニー リミテッド 縮環キナゾリン誘導体及びその使用
WO2018093818A1 (en) * 2016-11-15 2018-05-24 Temple University-Of The Commonwealth System Of Higher Education Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use
MX2022004736A (es) * 2019-10-21 2022-07-27 Alairion Inc Derivados de acido 3-(4-(11h-dibenzo [b, e] [1, 4] azepin-6-il)piperazin-1-il)- y 3-(4- dibenzo [b, f] [1, 4] oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)propanoico como moduladores de los receptores h1 y 5-ht2a para el tratamiento de los trastornos del sue?o.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642791A (en) * 1969-08-13 1972-02-15 Sandoz Ag Morpholino-1-substituted-2(1h)-quinazolinones
JPS5271483A (en) * 1975-12-11 1977-06-14 Sumitomo Chem Co Ltd Synthesis of 2(1h)-quinazolinone derivatives
CN1015459B (zh) * 1985-06-06 1992-02-12 田边制药株式会社 喹唑啉酮化合物的制备方法
GR1000821B (el) * 1988-11-22 1993-01-25 Tanabe Seiyaku Co Μεθοδος παραγωγης παραγωγων κιναζολινονης.
WO1998018781A2 (en) 1996-10-28 1998-05-07 Versicor, Inc. Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents
WO1998042688A1 (fr) 1997-03-26 1998-10-01 Sumitomo Pharmaceuticals Co., Ltd. Derives de 4-arylmethylene-1,4-dihydro-2h-azine
US6331538B1 (en) 1997-10-28 2001-12-18 Warner-Lambert Company 7-substituted quinazolin-2,4-diones useful as antibacterial agents
AU2074699A (en) * 1998-01-26 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel benzene-fused heterocyclic derivatives or salts thereof
ATE286883T1 (de) * 1999-11-05 2005-01-15 Smithkline Beecham Plc Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität
EP1248624A4 (en) 1999-11-23 2003-01-22 Smithkline Beecham Corp 3,4-DIHYDRO- (1H) -CHIRAZOLINE-2-ONES AND THE USE THEREOF AS CSBP / P38 KINASE INHIBITORS
AU2525701A (en) 1999-12-14 2001-06-25 Sanofi-Synthelabo Derivatives of quinazolinedione phthalimide, preparations thereof and their therapeutic uses
EP1345603A4 (en) * 2000-12-20 2004-09-08 Merck & Co Inc P38 KINASE INHIBITORS (HALO-BENZO CARBONYL) HETEROCYCLO- FUSIONNES PHENYL
US6998408B2 (en) * 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
KR20040010709A (ko) * 2001-06-15 2004-01-31 에프. 호프만-라 로슈 아게 5-ｈｔ6 수용체 친화력을 갖는 4-피페라지닐인돌 유도체
GB0203804D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
RS51042B (sr) * 2002-05-13 2010-10-31 F. Hoffmann-La Roche Ag. Derivati benzoksazina kao 5-ht6 modulatori i njihove primene

Also Published As

Publication number Publication date
JP2007517826A (ja) 2007-07-05
AR047958A1 (es) 2006-03-15
KR20060126720A (ko) 2006-12-08
ZA200605434B (en) 2008-02-27
CO5700763A2 (es) 2006-11-30
AU2005205016A1 (en) 2005-07-28
TW200530222A (en) 2005-09-16
EP1708713A1 (en) 2006-10-11
NO20062791L (no) 2006-08-01
US20070149510A1 (en) 2007-06-28
IL176631A0 (en) 2006-10-31
DE602005005298D1 (de) 2008-04-24
WO2005067933A1 (en) 2005-07-28
DE602005005298T2 (de) 2009-03-12
US7196087B2 (en) 2007-03-27
JP4533391B2 (ja) 2010-09-01
KR100843053B1 (ko) 2008-07-01
US20050165001A1 (en) 2005-07-28
ES2302174T3 (es) 2008-07-01
EP1708713B1 (en) 2008-03-12
ATE388712T1 (de) 2008-03-15
CN1909909B (zh) 2010-12-15
US7365063B2 (en) 2008-04-29
RU2006129464A (ru) 2008-02-27
CA2552681A1 (en) 2005-07-28
AU2005205016B2 (en) 2010-07-15
CN1909909A (zh) 2007-02-07

Similar Documents

Publication Publication Date Title
BRPI0506909A (pt) derivados de 1-benzil-5piperazin-1-il-3,4 diidro-1h-quinazolin-2-ona e os respectivos derivados de 1h-benzo (1,2,6) tiadiazina-2,2-dióxido e 1,4-diidro-benzo (d) (1,3)oxazin-2-ona como moduladores do receptor de 5-hidroxitriptamina (5-ht) para o tratamento de doenças do sistema nervoso central
BRPI0816767B8 (pt) composto 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridi¬nil-2'-onas 1',3'-dissubstituídas, composição farmacêutica e uso dos mesmos
BRPI0515412A (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BR112015021336A2 (pt) compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
EA201000331A1 (ru) 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны
MX2014006210A (es) Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
EA200901160A1 (ru) Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она
EA200901159A1 (ru) Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она
MX2009005449A (es) Compuesto heteromonociclico y uso del mismo.
AR068423A1 (es) Compuesto, composicion farmaceutica y uso del compuesto en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo relacionado con o afectado por el receptor de histamina-3 (h3) y proceso para la preparacion del compuesto
NO20091478L (no) Aminometyl-4-imidazoler
NO20073051L (no) Tetralin- og indanderivater og deres anvedelse
TW200719894A (en) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives
IL202236A0 (en) Prolinamide derivatives as nk3 antagonists
ATE435223T1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
PE20040763A1 (es) Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
MX2009012734A (es) Derivados de azaciclilbenzamida como antagonistas de histamina-3.
BR112012003916A2 (pt) derivados de pirrolidinas como antagonistas de receptores nk3
BRPI0414460A (pt) compostos derivados de carboxamida do tipo de amida, composição farmacêutica e respectivo uso
WO2007142904A3 (en) Benzoxazole and benzothiazole derivatives as 5-hydroxytrytamine-6 ligands
EA201001179A1 (ru) 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТРЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
BRPI0414597A (pt) derivados de benzofurano do tipo carbamoìla
PE20091016A1 (es) Compuestos de bencensulfonanilida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2205 DE 09/04/2013.